Flow is an FDA-cleared, prescription, at-home, non-drug treatment for moderate to severe major depressive disorder (MDD) in adults. It uses transcranial direct current stimulation (tDCS)—a low-level electrical current delivered through a wearable headset—to target brain networks involved in mood regulation, with guidance through a companion app and clinician oversight.
Why New Depression Treatments Are Needed
For many adults with depression, the challenge isn’t motivation or willingness to engage in care—it’s access. Traditional in-office neuromodulation treatments such as Transcranial Magnetic Stimulation (TMS) can be effective, but they often come with significant real-world barriers, including:
- The need for frequent in-office visits, often five days per week for four to six weeks
- Time away from work and difficulty coordinating schedules
- Childcare and transportation challenges, especially for daily appointments
- High deductibles and out-of-pocket costs, even when insurance coverage is available
- Insurance requirements such as step therapy, which may require patients to trial and fail multiple medications before approval
For many individuals, these logistical and financial hurdles—not the treatment itself—become the limiting factor. Effective depression care should fit into real life, not require patients to put their lives on hold in order to receive it.
What Is Flow Depression Treatment?
Flow is a prescription-only, at-home treatment for depression developed by Flow Neuroscience. It uses transcranial direct current stimulation (tDCS), a non-invasive form of brain stimulation that delivers a low-level electrical current to targeted areas of the brain involved in mood regulation.
The Flow system includes:
- A wearable tDCS headset used at home
- A companion mobile app that guides treatment sessions and supports mood tracking
Flow was recently approved by the FDA in the United States for the treatment of moderate to severe major depressive disorder in adults. Importantly, Flow requires a prescription from a licensed healthcare provider, reinforcing that this is a medical treatment—not a consumer wellness device.
The First At-Home, Non-Drug Treatment for Moderate to Severe Depression
Until recently, non-drug treatments that work directly on the brain—such as in-office Transcranial Magnetic Stimulation (TMS)—required patients to come to a clinic nearly every day for several weeks. While these treatments can help some people with depression, the time commitment, cost, and logistics often make them hard to complete.
Flow changes how this type of depression treatment can be delivered. It is a prescription, at-home, non-drug therapy that allows people to receive brain-based treatment for depression from home, while still being guided by a healthcare provider.
What the Research Shows About Flow and Remission
Flow’s FDA clearance was supported by clinical research showing strong results for people with moderate to severe major depressive disorder.
In a large clinical study called the EMPOWER trial, researchers followed 173 adults with moderate to severe unipolar depression over 10 weeks. The study compared Flow to a placebo (sham treatment).
- 57.5% of people using Flow reached remission within 10 weeks
- Remission means depression symptoms improved to the point that they no longer met criteria for major depression
- Flow performed significantly better than placebo, showing that the benefit was not due to chance
Additional real-world data and ongoing studies have shown similar results, suggesting that many people using Flow experience meaningful symptom relief—and in some cases, full remission.
By removing the need for daily clinic visits, Flow expands access to a treatment option that is not only effective, but also realistic for people balancing work, family, and daily life.
Who May Be a Good Candidate for Flow?
Flow may be appropriate for adults with moderate to severe major depressive disorder who:
- Prefer a non-medication treatment option
- Have had limited benefit from antidepressants
- Experienced medication side effects
- Face barriers to frequent in-office treatments
- Are seeking an evidence-based option that fits into daily life
As with all depression treatments, Flow is not appropriate for everyone. A comprehensive psychiatric evaluation is essential to confirm diagnosis, assess safety, and determine whether this treatment is clinically appropriate.
Flow Availability at Different Mental Health Program
At Different Mental Health Program, we are closely monitoring FDA-cleared prescribing pathways and national availability for Flow.
While timelines are still being finalized, we anticipate potential availability beginning in the second quarter of 2026. We are proud to be preparing to offer this at-home, prescription, non-drug depression treatment to clients seeking a different and forward-thinking approach to managing depression.
As with all care at Different Mental Health Program, Flow will be offered only after a thorough psychiatric evaluation to ensure safety and appropriateness.
Join the Flow Interest List
If you’re exploring new depression treatments for 2026 and are interested in a prescription, at-home, non-drug option, you may join our interest list to receive updates as availability becomes clearer.
Joining the interest list:
- Does not guarantee eligibility
- Does not replace a psychiatric evaluation
- Allows us to share updates on access and next steps
Frequently Asked Questions About Flow Depression
Yes. Flow is a prescription-only medical device and must be prescribed by a licensed healthcare provider.
TMS requires frequent in-office visits, while Flow is designed for at-home use with clinician oversight, reducing common access barriers.
We anticipate potential availability in Q2 2026, pending finalized prescribing and distribution pathways.
Flow uses transcranial direct current stimulation (tDCS), a non-invasive form of brain stimulation that has been studied in depression treatment. As with any medical treatment, Flow is prescribed only after a clinical evaluation to assess safety and appropriateness, and it is used under healthcare provider guidance.
Flow treatment is structured and guided through a companion app. Specific treatment duration and schedules may vary based on clinical guidance and individual response. Your provider will review expectations during evaluation and follow-up.
Flow may be used alone or alongside other treatments, such as antidepressant medications or psychotherapy, depending on individual clinical needs. Treatment decisions are made collaboratively with a prescribing provider.
No. While both Flow and TMS are forms of neuromodulation, they use different technologies and delivery models. TMS requires in-office treatment with magnetic stimulation, while Flow uses low-level electrical stimulation and is designed for at-home use with a prescription.
Flow may not be appropriate for everyone. Certain medical or neurological conditions may affect eligibility. A comprehensive psychiatric and medical evaluation is required before prescribing to ensure safety.
